Domov › Nemalicelični pljučni rak › Illinois › Chicago
Klinične študije za Nemalicelični pljučni rak v Chicago, IL
61 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Chicago in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- in še 1
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Vključevanje udeležencevFaza 3
- The University of Chicago Medical Center ( Site 0118), Chicago
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Vključevanje udeležencevFaza 3
- University of Illinois Cancer Center, Chicago
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Vključevanje udeležencevFaza 2
- Rush MD Anderson Cancer Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- University of Chicago Hospital, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #26, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- University of Illinois Cancer Center, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- Northwestern University, Chicago
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Vključevanje udeležencevFaza 3
- University of Chicago Medical Center, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Vključevanje udeležencevFaza 3
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Illinois Cancer Specialists, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Vključevanje udeležencevFaza 3
- University of Illinois Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Research Site, Chicago
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- University of Illinois at Chicago, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Research Site, Chicago
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- City of Hope, Chicago, Chicago
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Research Site, Chicago
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Vključevanje udeležencevFaza 2/3
- Rush University Medical Center, Chicago
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Vključevanje udeležencevFaza 3
- University of Illinois at Chicago, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Northwestern University Feinberg School of Medicine, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Research Site, Chicago
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Vključevanje udeležencevFaza 3
- Clinical Study Site, Chicago
- Clinical Study Site, Chicago
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Vključevanje udeležencevFaza 3
- Northwestern University, Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Vključevanje udeležencevFaza 2/3
- University of Chicago, Chicago
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2/3
- The University of Chicago Medical Center /ID# 262259, Chicago
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- Northwestern University, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Vključevanje udeležencevFaza 1
- University of Chicago, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Northwestern University, Chicago
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Vključevanje udeležencevFaza 3
- Research Site, Chicago
- Research Site, Chicago
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Vključevanje udeležencevFaza 3
- University of Chicago Medical Center ( Site 0145), Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Vključevanje udeležencevFaza 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Vključevanje udeležencevFaza 3
- Northwestern University, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Vključevanje udeležencevFaza 1/2
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Vključevanje udeležencevFaza 1/2
- University of Chicago, Chicago
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Northwestern University, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Vključevanje udeležencevFaza 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- The University of Chicago Medical Center (UCMC), Chicago
Study of XB010 in Subjects With Solid Tumors
Vključevanje udeležencevFaza 1
- University of Chicago Medical Center, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Vključevanje udeležencevFaza 1/2
- Northwestern Memorial Hospital, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Vključevanje udeležencev
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Vključevanje udeležencevFaza 1/2
- University of Chicago, Chicago
Segmentectomy After Induction Therapy (SAINT)
Vključevanje udeležencev
- Northwestern University, Chicago
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Research Site, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Vključevanje udeležencevFaza 2
- University of Illinois Cancer Center, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Vključevanje udeležencevFaza 1/2
- Northwestern Memorial Hospital, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Vključevanje udeležencev
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of Chicago, Chicago
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Vključevanje udeležencevOpazovalna študija
- University of Chicago, Chicago
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY120 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Columbus, OH56 študij
- Washington, DC55 študij
- Seattle, WA53 študij
Druge študije v Chicago
- Rak dojke58 študij
- Rak (vse vrste)51 študij
- Metastatski rak45 študij
- Rak prostate45 študij
- Debelost41 študij
- Rak pljuč41 študij
- Rak jajčnikov36 študij
- Možganska kap34 študij
- Kolorektalni rak33 študij
- Srčno popuščanje31 študij
- Prekomerna telesna teža28 študij
- Ploščatocelični karcinom glave in vratu26 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.